Working Memory and Physical Exercise Training in Patients With Mild Cognitive Impairment

Sponsor
University of Maryland, Baltimore (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05948930
Collaborator
(none)
90
1
3
11
8.2

Study Details

Study Description

Brief Summary

The prevalence of dementia will double in the next three decades in the U.S.; effective treatment or prevention for dementia is urgently needed. The current exploratory project aims to evaluate and understand how the brain and cognition may improve after a 12-week intervention that combines brain training and aerobic exercise training to improve brain function, both in those with mild cognitive impairment (some with possible prodromal Alzheimer's disease) and with healthy aging. Findings from this pilot project will guide and refine the development of a future larger clinical trial that aligns with the goals of the National Alzheimer's Plan of Action (NAPA), especially regarding "Prevent and Effectively Treat Alzheimer's Disease (AD) by 2025.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Progressive aerobic exercise
  • Behavioral: Adaptive cognitive training
  • Behavioral: Combined
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
90 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Supportive Care
Official Title:
Adaptive Working Memory and Physical Exercise Training to Improve Brain and Mitochondrial Function in MCI
Anticipated Study Start Date :
Aug 1, 2023
Anticipated Primary Completion Date :
Jul 1, 2024
Anticipated Study Completion Date :
Jul 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Aerobic Exercise

Progressive aerobic exercise 3x/week for 12 weeks.

Behavioral: Progressive aerobic exercise
Progressive aerobic exercise

Experimental: Cognitive Training

Adaptive cognitive training on Cogmed 5x/week for a total of 25 sessions in 5-8 weeks.

Behavioral: Adaptive cognitive training
Adaptive cognitive training

Experimental: Combined Cognitive and Aerobic Exercise

Combined progressive aerobic exercise 3x/week for 12 weeks and adaptive cognitive training on Cogmed 5x/week for a total of 25 sessions in 5-8 weeks simultaneously.

Behavioral: Combined
Combine adaptive cognitive and progressive aerobic exercise training

Outcome Measures

Primary Outcome Measures

  1. Changes in Brain imaging measures [At baseline and at 4 weeks after the corresponding training program.]

    Changes in brain imaging measures from morphometry (T1-weighted and diffused tensor imaging), relative cerebral blood flow (from Arterial spin labeling MR perfusion, ASL), and BOLD signal from fMRI.

  2. Changes in cognitive performance, emotions, and motor function based on NIH toolbox [At baseline and at 4 weeks after the corresponding training program.]

    Changes in cognitive performance, emotions, and motor function scores measured by the NIH Toolbox®

  3. Changes in executive function using the Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A) [At baseline and at 4 weeks after the corresponding training program.]

    Changes in executive function using the Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A)

  4. Changes in Blood Bioenergetic Markers [At baseline and at 4 weeks after the corresponding training program.]

    Platelet mitochondrial respiration (OCR) and extracellular acidification rates (ECAR) will be evaluated to assess bioenergetic profiles in platelets isolated from whole blood of fasted participants. OCR will be measured using a Seahorse XFe96 as the high throughput platform. Measurements of OCR/ECAR will be performed with the following modifications. Platelets will be isolated from whole blood with a Beckman Allegra X-30R centrifuge. Platelets will be counted using a Nexcelom Bioscience Cellometer (Lawrence, MA) using calcein AM dye to enable seeding of 10,000,000 platelets per well.

Secondary Outcome Measures

  1. VO2peak [At baseline and within one week after the corresponding training program.]

    VO2peak will be used as the primary measure of aerobic capacity. Subjects will be asked to exercise to voluntary exhaustion during a treadmill test using a modified Bruce protocol. Oxygen (O2) consumption, carbon dioxide (CO2) production, and minute ventilation will be measured breath-by-breath using a metabolic cart and the average of the final two 20 second values of O2 consumption are VO2peak.

Eligibility Criteria

Criteria

Ages Eligible for Study:
50 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Adult men and women of all races and ethnicities who are 50-80 years of age will be eligible.

  • Only sedentary adults will be eligible (engaging in structured activity for exercise (<3x/week).

  • Ability to use, and accessibility to, an iPad or computer.

  • Fluent in English.

  • The diagnosis of MCI will first be confirmed at the screening evaluation using the clinical dementia rating (CDR) scale and the MoCA. We will also evaluate their ADL using instrumental activities of daily living (IADL) to ensure they have preserved independence in functional abilities despite the cognitive deficits. The primary caregivers will be interviewed (either in person or by phone) for the participants' IADL to corroborate the independent functional status.

Exclusion Criteria:
  • Does not have access to a computer or internet to perform the Cogmed® training AND is unwilling to come to the lab for the training.

  • Unable to undergo a MRI investigation based on claustrophobia or metal foreign bodies.

  • Symptomatic heart disease, CAD, CHF, uncontrolled hypertension, significant cardiovascular disorders (on EKG and graded exercise test) that would prevent the participant from the exercise training; neurologic, musculoskeletal, or other condition that limits the subject's ability to complete study physical assessments.

  • Estimated verbal IQ below 70 (based on the Wechsler Test of Adult Reading) which would invalidate the informed consent process for the study.

  • Self-reported moderate to severe substance use disorder(s) (e.g., self-reported intake

3 oz liquor, or three 4 oz glasses of wine, or three 12 oz cans of beer per day or illicit drug use).

  • Severe chronic or acute medical or other (non-MCI) neuropsychiatric conditions that might confound the cognitive or brain imaging measures (e.g., liver function tests

2.5 normal range or evidence for renal failure).

  • Body mass index >40 kg/m2.

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Maryland Baltimore Baltimore Maryland United States 21201

Sponsors and Collaborators

  • University of Maryland, Baltimore

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Linda Chang, Dr., University of Maryland, Baltimore
ClinicalTrials.gov Identifier:
NCT05948930
Other Study ID Numbers:
  • HP-00105789
First Posted:
Jul 17, 2023
Last Update Posted:
Jul 17, 2023
Last Verified:
Jul 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 17, 2023